Skip to main content
Top
Published in: Hepatology International 3/2020

Open Access 01-05-2020 | Human Immunodeficiency Virus | Original Article

Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort

Authors: Maria Giovanna Quaranta, Luigina Ferrigno, Monica Monti, Roberto Filomia, Elisa Biliotti, Andrea Iannone, Guglielmo Migliorino, Barbara Coco, Filomena Morisco, Maria Vinci, Roberta D’Ambrosio, Liliana Chemello, Marco Massari, Donatella Ieluzzi, Francesco Paolo Russo, Pierluigi Blanc, Gabriella Verucchi, Massimo Puoti, Maria Grazia Rumi, Francesco Barbaro, Teresa Antonia Santantonio, Alessandro Federico, Luchino Chessa, Ivan Gentile, Massimo Zuin, Giustino Parruti, Giulia Morsica, Loreta A. Kondili, on behalf of PITER Collaborating Group

Published in: Hepatology International | Issue 3/2020

Login to get access

Abstract

Background

Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated.

Methods

Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis.

Results

93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 (range 6–44.6) and 24.6 (range 6.8–47.3) months, respectively. No difference in the cumulative HCC incidence and hepatic decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR] = 1.08; 95% CI 1.04–1.13), male sex (HR = 2.76; 95% CI 1.28–5.96), lower albumin levels (HR = 3.94; 95% CI 1.81–8.58), genotype 3 (HR = 5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR = 1.99, 95% CI 1.01–3.95) were independently associated with HCC incidence. Older age (HR = 1.03; 95% CI 1.00–1.07), male sex (HR = 2.13; 95% CI 1.06–4.26) and lower albumin levels (HR = 3.75; 95% CI 1.89–7.46) were independently associated with the appearance of a decompensating event after viral eradication.

Conclusion

Different demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progression is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication.
Literature
1.
go back to reference Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016;16(7):797–808PubMedCrossRef Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016;16(7):797–808PubMedCrossRef
2.
go back to reference Macías J, Márquez M, Téllez F, Merino D, Jiménez-Aguilar P, López-Cortés LF, Ortega E, et al. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis 2013;57(10):1401–1408PubMedCrossRef Macías J, Márquez M, Téllez F, Merino D, Jiménez-Aguilar P, López-Cortés LF, Ortega E, et al. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis 2013;57(10):1401–1408PubMedCrossRef
3.
go back to reference Merchante N, Merino E, López-Aldeguer J, Jover F, Delgado-Fernández M, Galindo MJ, Ortega E, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013;56(1):143–150PubMedCrossRef Merchante N, Merino E, López-Aldeguer J, Jover F, Delgado-Fernández M, Galindo MJ, Ortega E, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013;56(1):143–150PubMedCrossRef
4.
go back to reference Klein MB, Althoff KN, Jing Y, North American AIDS Cohort Collaboration on Re- search and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis 2016;63(9):1160–1167PubMedPubMedCentral Klein MB, Althoff KN, Jing Y, North American AIDS Cohort Collaboration on Re- search and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis 2016;63(9):1160–1167PubMedPubMedCentral
5.
go back to reference Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211–221PubMedCrossRef Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211–221PubMedCrossRef
6.
go back to reference Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483–1493PubMedCrossRef Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483–1493PubMedCrossRef
7.
go back to reference Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;393(10179):1453–1464PubMedCrossRef Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;393(10179):1453–1464PubMedCrossRef
8.
go back to reference Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int 2019;13(1):66–74PubMedCrossRef Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int 2019;13(1):66–74PubMedCrossRef
9.
go back to reference Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155(2):411–421PubMedCrossRef Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155(2):411–421PubMedCrossRef
10.
go back to reference ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016;65(4):734–740CrossRef ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016;65(4):734–740CrossRef
12.
go back to reference Kondili LA, Vella S, PITER Collaborating Group. PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. Dig Liver Dis 2015;47(9):741–743PubMedCrossRef Kondili LA, Vella S, PITER Collaborating Group. PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. Dig Liver Dis 2015;47(9):741–743PubMedCrossRef
13.
go back to reference Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41(1):48–54PubMedCrossRef Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41(1):48–54PubMedCrossRef
14.
go back to reference Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol 2017;67(1):23–31PubMedCrossRef Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol 2017;67(1):23–31PubMedCrossRef
15.
go back to reference d’Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, et al. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017;12(5):e0177402PubMedPubMedCentralCrossRef d’Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, et al. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017;12(5):e0177402PubMedPubMedCentralCrossRef
16.
go back to reference Corma-Gómez A, Morano L, Téllez F, Rivero-Juárez A, Real LM, Alados JC, Ríos-Villegas MJ, et al. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS 2019;33(7):1167–1174PubMedCrossRef Corma-Gómez A, Morano L, Téllez F, Rivero-Juárez A, Real LM, Alados JC, Ríos-Villegas MJ, et al. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS 2019;33(7):1167–1174PubMedCrossRef
17.
go back to reference Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, et al. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: results From the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis 2016;63(10):1320–1324PubMedCrossRef Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, et al. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: results From the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis 2016;63(10):1320–1324PubMedCrossRef
18.
go back to reference Janjua NZ, Kuo M, Chong M, Yu A, Alvarez M, Cook D, Armour R, et al. Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): design and Characteristics of Linked and Unlinked Participants. PLoS ONE 2016;11(3):e0150176PubMedPubMedCentralCrossRef Janjua NZ, Kuo M, Chong M, Yu A, Alvarez M, Cook D, Armour R, et al. Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): design and Characteristics of Linked and Unlinked Participants. PLoS ONE 2016;11(3):e0150176PubMedPubMedCentralCrossRef
19.
go back to reference Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, et al. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110(8):1169–1177PubMedPubMedCentralCrossRef Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, et al. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110(8):1169–1177PubMedPubMedCentralCrossRef
20.
go back to reference Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, Caroleo B, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26(4):1006–1011PubMedCrossRef Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, Caroleo B, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26(4):1006–1011PubMedCrossRef
22.
go back to reference Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998;29:701–706PubMedCrossRef Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998;29:701–706PubMedCrossRef
24.
go back to reference Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M, collaborators. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis 2019;51:310–317PubMedCrossRef Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M, collaborators. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis 2019;51:310–317PubMedCrossRef
25.
go back to reference Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int 2019;13(3):293–301PubMedCrossRef Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int 2019;13(3):293–301PubMedCrossRef
26.
go back to reference Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol 2018;69(2):345–352PubMedCrossRef Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol 2018;69(2):345–352PubMedCrossRef
27.
go back to reference Kondili LA, Quaranta MG, Rosato S, Weimer LE, D’Angelo F, Coppola C, et al. Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort. Hepatology 2018;68(S1):889A–890A Kondili LA, Quaranta MG, Rosato S, Weimer LE, D’Angelo F, Coppola C, et al. Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort. Hepatology 2018;68(S1):889A–890A
28.
go back to reference Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell’Unto C, et al. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf 2019;18(7):603–610PubMedCrossRef Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell’Unto C, et al. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf 2019;18(7):603–610PubMedCrossRef
29.
go back to reference van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66(3):485–493PubMedCrossRef van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66(3):485–493PubMedCrossRef
Metadata
Title
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort
Authors
Maria Giovanna Quaranta
Luigina Ferrigno
Monica Monti
Roberto Filomia
Elisa Biliotti
Andrea Iannone
Guglielmo Migliorino
Barbara Coco
Filomena Morisco
Maria Vinci
Roberta D’Ambrosio
Liliana Chemello
Marco Massari
Donatella Ieluzzi
Francesco Paolo Russo
Pierluigi Blanc
Gabriella Verucchi
Massimo Puoti
Maria Grazia Rumi
Francesco Barbaro
Teresa Antonia Santantonio
Alessandro Federico
Luchino Chessa
Ivan Gentile
Massimo Zuin
Giustino Parruti
Giulia Morsica
Loreta A. Kondili
on behalf of PITER Collaborating Group
Publication date
01-05-2020
Publisher
Springer India
Published in
Hepatology International / Issue 3/2020
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-020-10034-0

Other articles of this Issue 3/2020

Hepatology International 3/2020 Go to the issue